Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19978286 | 0.86 | PAOX (0.47) | SMN1; SMN2ALDH1A1TSHRKAT2BLMNA | |
| SCHEMBL4489670 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2ALDH1A1KDM4ETSHRCACNA1C | |
| SCHEMBL1174392 | 0.84 | — | — | |
| SCHEMBL5767349 | 0.82 | KAT2B (0.43) | ALDH1A1TSHRKAT2BLMNAL3MBTL1 | |
| SCHEMBL6764084 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1KDM4ETSHRKAT2B | |
| SCHEMBL4133149 | 0.81 | CNR1 (0.39) | SMN1; SMN2ALDH1A1KDM4ETSHRTP53 | |
| SCHEMBL5483874 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1KDM4ETSHRCACNA1C | |
| SCHEMBL1725970 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1KDM4ETSHRMAPT | |
| SCHEMBL65886 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1KDM4ETSHRMAPT | |
| SCHEMBL10409891 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1TSHRMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023193789-A1 | WEE1 DEGRADING COMPOUNDS | BEIJING NEOX BIOTECH LIMITED (CN) | 2023-10-12 | — | — | WO | disclosed |
| CN-116829570-A | WEE1 degrading compounds | 北京星奇原生物科技有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116283977-A | Inhibitors of αvβ6 integrin | 莫菲克医疗股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-110573499-B | Inhibitors of αvβ6 integrin | 莫菲克医疗股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-3643704-B1 | NEW INTERMEDIATES FOR THE PREPARATION OF REMIFENTANIL HYDROCHLORIDE | HAMELN PHARMA GMBH (DE) | 2020-12-16 | — | — | EP | disclosed |
| US-10844014-B2 | Intermediates for the preparation of remifentanil hydrochloride | HAMELN PHARMA GMBH (DE) | 2020-11-24 | — | — | US | disclosed |
| US-20200131127-A1 | INTERMEDIATES FOR THE PREPARATION OF REMIFENTANIL HYDROCHLORIDE | HAMELN PHARMA PLUS GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
| EP-3643704-A1 | NEW INTERMEDIATES FOR THE PREPARATION OF REMIFENTANIL HYDROCHLORIDE | hameln pharma plus gmbh (DE) | 2020-04-29 | — | — | EP | disclosed |
| EP-3286172-B1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| EP-3286172-B1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20100016601-A1 | PROCESS FOR PREPARING REMIFENTANIL, INTERMEDIATES THEREOF, USE OF SAID INTERMEDIATES AND PROCESSES FOR THE PREPARATION THEREOF | KERN PHARMA, S.L. | 2010-01-21 | — | — | US | disclosed |
| WO-2007144391-A1 | PROCESS FOR PREPARING REMIFENTANIL, INTERMEDIATES THEREOF, USE OF SAID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION | KERN PHARMA, S.L. (ES) | 2007-12-21 | — | — | WO | disclosed |
| EP-1867635-A1 | Process for preparing remifentanil, intermediates thereof, use of said intermediates and processes for their preparation | KERN PHARMA, S.L. (ES) | 2007-12-19 | — | — | EP | disclosed |
| EP-1126838-A4 | NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20030207919-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX S.A. (FR) | 2003-11-06 | — | — | US | disclosed |
| US-6593347-B2 | Especially a nitrosated and/or nitrosylated arylpropionic acid, arylacetic acid, enolic anilide or an oxicam | NITROMED, INC. | 2003-07-15 | — | — | US | disclosed |
| US-20020016322-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use | NICOX S.A. (FR) | 2002-02-07 | — | — | US | disclosed |
| US-6297260-B1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED, INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1126838-A1 | NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000025776-A1 | NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016322-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use | NOS2, NOS3, NOS1 | SMN1; SMN2 2977/4885ALDH1A1 1076/4885KDM4E 4320/4885 |
| US-10844014-B2 | Intermediates for the preparation of remifentanil hydrochloride | OPRK1, OPRM1, OPRD1 | SMN1; SMN2 1422/4885ALDH1A1 1041/4885KDM4E 486/4885 |
| US-20200131127-A1 | INTERMEDIATES FOR THE PREPARATION OF REMIFENTANIL HYDROCHLORIDE | OPRK1, OPRM1, OPRD1 | SMN1; SMN2 1422/4885ALDH1A1 1041/4885KDM4E 486/4885 |
| US-20100016601-A1 | PROCESS FOR PREPARING REMIFENTANIL, INTERMEDIATES THEREOF, USE OF SAID INTERMEDIATES AND PROCESSES FOR THE PREPARATION THEREOF | OPRK1, CYP3A43, CYP3A4 | SMN1; SMN2 1358/4885ALDH1A1 786/4885KDM4E 778/4885 |
| US-20030207919-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NOS2, NOS1, NOS3 | SMN1; SMN2 2381/4885ALDH1A1 360/4885KDM4E 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.